Skip to Main Content
Diseases of the Digestive System - Liver, Phase IIA

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

What is the purpose of this trial?

The main purpose of this study is to determine the safety and tolerability of PLN-74809 compared to a placebo, when taken daily for up to 12 weeks. The study also aims to determine how the body processes the study medication and assess any changes in the condition PSC.

If you have been diagnosed with primary sclerosing cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts inside and outside the liver you could be eligible to participate in a research study by Pliant Therapeutics, investigating a medication named PLN-74809 for the treatment of PSC.

  • Trial with
    Pliant Therapeutics Inc.
  • Ages
    18 years - 75 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Suzie Christopher

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    07/23/2024
  • Study HIC
    #2000029307